Sherene Loi, MBBS, PhD, FRACP, FAHMS, Peter MacCallum Cancer Centre at the University of Melbourne, Melbourne, Australia, discusses current attitudes towards immunotherapy use in early-stage triple negative breast cancer (TNBC). Clinical trial evidence has shown improved pathologic complete response (pCR) rates attributable to neoadjuvant immunotherapy in TNBC. However, current data only reflects short-term outcomes, and how these findings will translate to long-term survival benefits is unclear. Prof. Loi also discusses preclinical investigations into the best biological setting for immunotherapy, sharing data from mouse models that support the use of a neoadjuvant approach. This interview took place during the 17th St. Gallen International Breast Cancer Conference.